SCHEDULE: Vanguard Group Amends Supernus Pharmaceuticals Ownership

The Vanguard Group reported 0% beneficial ownership in Supernus Pharmaceuticals Inc. following an internal realignment of its reporting structure.

Summary

• The Vanguard Group filed an Amendment No. 7 to its Schedule 13G for Supernus Pharmaceuticals Inc.
• The filing indicates that The Vanguard Group now beneficially owns 0% of Supernus Pharmaceuticals Inc. common stock.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report their beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities held by these disaggregated subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Supernus Pharmaceuticals Inc. as it primarily reflects an internal organizational and reporting change within The Vanguard Group, rather than a direct investment decision based on the issuer's fundamentals.

Management Comments

• The Vanguard Group, Inc. went through an internal realignment on January 12, 2026.
• Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.
• Securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional investors like Vanguard frequently adjust their internal reporting structures and portfolio management strategies. This specific filing reflects an internal organizational change within Vanguard rather than a strategic divestment decision related to Supernus Pharmaceuticals Inc.'s performance or outlook. The disaggregation of reporting means that while Vanguard's parent entity no longer reports ownership, its underlying funds or divisions may still hold shares, but will now report them independently.

Management Changes

Stakeholder Impact

• Shareholders: The immediate impact on Supernus Pharmaceuticals Inc. shareholders is likely minimal, as the underlying holdings by Vanguard's various funds may still exist, just reported differently. It clarifies that the parent entity, The Vanguard Group, no longer directly reports beneficial ownership.
• Investment Professionals: Provides clarity on Vanguard's reporting structure for Supernus Pharmaceuticals Inc. holdings, requiring them to look at individual Vanguard funds/divisions for specific ownership data.

Key Dates

Recommendation

This filing primarily details an internal organizational change within The Vanguard Group regarding how it reports beneficial ownership, rather than a direct investment decision based on Supernus Pharmaceuticals Inc.'s performance. The 0% reported ownership by the parent entity does not necessarily mean a complete divestment by all Vanguard-managed funds. Therefore, it does not provide sufficient information to warrant a 'buy' or 'sell' recommendation for Supernus Pharmaceuticals Inc. based solely on this filing. A 'hold' is appropriate as it's a reporting update, not a fundamental change in the issuer's outlook.

Keywords

Supernus Pharmaceuticals, Vanguard Group, Schedule 13G, beneficial ownership, institutional ownership, SEC filing, common stock, internal realignment